Formulation R&D, Custom Pharmaceutical Services, Dr. Reddy's Laboratories Ltd., Miyapur, R R District, Hyderabad, 500049, India.
Advanced Characterization Laboratory, Integrated Product Development Organisation, IPDO- Innovation Plaza, Dr. Reddy's Laboratories, Bachupally, R R District, Hyderabad, 500090, India.
AAPS PharmSciTech. 2018 Jan;19(1):326-337. doi: 10.1208/s12249-017-0808-z. Epub 2017 Jul 18.
Solubility challenge for a poorly water-soluble drug gets further intensified when it is weakly ionic because the most common solubility enhancement technique, salt formation, becomes less feasible. Salt screening for such drugs often concludes with either a difficult to crystalize salt or an unstable salt, leading the scientists to explore other solubility enhancement technique like amorphous solid dispersions which is comparatively costlier, time-consuming and may require use of hazardous organic solvents. Present study evaluated in situ salification in polar protic solvents for dissolving poorly water-soluble drug Itraconazole which is weakly ionic and not very amenable to formation of stable inorganic salts. Through systematic selection of solvents, counterions and polymers, an amorphous solid dispersion of drug salt was obtained. In vitro characterizations with polarized light microscopy (PLM), modulated differential scanning calorimetry (mDSC), Fourier transform infrared spectroscopy (FTIR) and X-ray powder diffraction (XRD) confirmed the physical and chemical stability of the amorphous solid dispersion. In vivo pharmacokinetic study showed that the drug salt amorphous solid dispersion achieved 45 times higher plasma exposure compared to crystalline drug. This study provides one of the first data sets for the hypothesis that in situ drug salts can be utilized for manufacturing amorphous solid dispersions of weakly ionic drugs and leverages the solubility advantage of salts and amorphous state.
当药物具有弱离子性时,其水溶性较差的问题会进一步加剧,因为最常见的提高溶解度的方法——成盐,变得不太可行。对于这类药物,进行盐筛选通常会得到难以结晶的盐或不稳定的盐,这使得科学家们转而探索其他提高溶解度的技术,如无定形固体分散体,虽然这种方法相对更昂贵、耗时,并且可能需要使用危险的有机溶剂。本研究评估了在极性质子溶剂中就地成盐来溶解水溶性较差的弱离子药物伊曲康唑。通过对溶剂、反离子和聚合物的系统选择,得到了药物盐的无定形固体分散体。偏光显微镜 (PLM)、调制差示扫描量热法 (mDSC)、傅里叶变换红外光谱 (FTIR) 和 X 射线粉末衍射 (XRD) 的体外特征证实了无定形固体分散体的物理和化学稳定性。体内药代动力学研究表明,与晶型药物相比,药物盐无定形固体分散体的血浆暴露量提高了 45 倍。这项研究提供了首个数据集之一,支持了这样一种假设,即原位药物盐可用于制造弱离子药物的无定形固体分散体,并利用盐和无定形状态的溶解度优势。